- Home
- CNEY vs CNSP Comparison
CNEY vs CNSP Comparison
Compare CNEY & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | CNSP |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.9M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNEY | CNSP |
|---|---|---|
| Price | $0.74 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 394.2K | ★ 2.1M |
| Earning Date | 02-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.73 |
| 52 Week High | $3.25 | $10.59 |
Technical Indicators
Market Signals| Indicator | CNEY | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 71.54 |
| Support Level | $0.54 | $5.62 |
| Resistance Level | $0.80 | $8.73 |
| Average True Range (ATR) | 0.08 | 0.85 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 84.11 | 52.64 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.